← Back to Search

Stem Cell Therapy

Stem Cells for Retinal Disease

Phase 1
Waitlist Available
Led By Susanna s Park, MD PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >18 years of age
Vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion, or diabetic retinopathy
Must not have
Other concurrent retinal or optic nerve disease affecting vision
Screening 3 weeks
Treatment Varies
Follow Up 1 day to 6 months
Awards & highlights


This trial is to see if it's safe to inject stem cells from bone marrow into the eye to treat blindness from various retinal conditions.

Who is the study for?
This trial is for adults over 18 with vision loss from conditions like macular degeneration or diabetic retinopathy. Participants must have a visual acuity ranging from 20/100 to hand movement and the affected eye should be the one with worse vision. They shouldn't have had certain eye treatments in the last 6 months, no blood disorders, active diseases, or be on immunosuppressive therapy.Check my eligibility
What is being tested?
The study tests injecting CD34+ stem cells directly into the eye of patients who are blind due to various retinal diseases. It aims to assess if this approach is safe and can feasibly improve sight.See study design
What are the potential side effects?
Potential side effects may include discomfort at injection site, inflammation inside the eye, increased intraocular pressure, bleeding, infection risk post-procedure and possible immune reaction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am older than 18 years.
I have vision loss due to a specific eye condition.
I haven't had treatments for eye swelling or abnormal blood vessels in the eye in the last 6 months.
I am not on any immunosuppressive therapy.
I have had vision loss for more than 3 months.
I do not have any active eye or systemic diseases.
I do not have any blood clotting or blood disorders.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have an eye condition affecting my vision.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of ocular adverse events
Secondary outcome measures
The number of stem cells isolated and injected into the study eye
Other outcome measures
Incidence and severity of systemic adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stem cell treatedExperimental Treatment1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Diabetic Retinopathy include anti-VEGF injections, corticosteroids, laser therapy, and vitrectomy. Anti-VEGF injections work by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and leakage. Corticosteroids reduce inflammation and edema in the retina. Laser therapy seals leaking blood vessels and prevents further vision loss. Vitrectomy removes blood and scar tissue from the vitreous. These treatments are crucial as they help manage symptoms and prevent progression of the disease. Similar to these treatments, the CD34+ stem cell injection trial aims to repair or replace damaged retinal cells, offering a regenerative approach that could potentially restore vision and address the underlying damage caused by Diabetic Retinopathy.

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
919 Previous Clinical Trials
4,720,877 Total Patients Enrolled
Susanna s Park, MD PhDPrincipal InvestigatorUniversity of California Davis Eye Center

Media Library

CD34+ bone marrow stem cells (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01736059 — Phase 1
Diabetic Retinopathy Research Study Groups: Stem cell treated
Diabetic Retinopathy Clinical Trial 2023: CD34+ bone marrow stem cells Highlights & Side Effects. Trial Name: NCT01736059 — Phase 1
CD34+ bone marrow stem cells (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01736059 — Phase 1
~1 spots leftby Oct 2025